Voyager Therapeutics (VYGR) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.90, -7.77% vs the prior close of $2.06.
- Volume 573.21K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VYGR slides 7.8% to $1.90, a 52-week low. Closed at $1.90, -7.77% vs the prior close of $2.06. Day range $1.89–$2.05, opened at $2.05.
VYGR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — VYGR slides 7.8% to $1.90, a 52-week low
- Closed at $1.90, -7.77% vs the prior close of $2.06. Day range $1.89–$2.05, opened at $2.05.
- Volume was 573.21K shares, 1.0x its 50-day average of 577.76K.
- Price is -36.4% vs its 50-day average ($2.99) and -46.7% vs its 200-day average ($3.57).
- 52-week range $1.89–$5.55; today's close sits at 0% of that range, 65.8% below the 52-week high.
Oct 15, 2026 — VYGR rises 2.5% to $2.06
- Closed at $2.06, +2.49% vs the prior close of $2.01. Day range $2.00–$2.10, opened at $2.00.
- Volume was 719.30K shares, 1.3x its 50-day average of 575.02K.
- Price is -31.7% vs its 50-day average ($3.01) and -42.4% vs its 200-day average ($3.58).
- 52-week range $1.99–$5.55; today's close sits at 2% of that range, 62.9% below the 52-week high.
Oct 14, 2026 — VYGR slides 6.5% to $2.01, a 52-week low on 2.1x normal volume
- Closed at $2.01, -6.51% vs the prior close of $2.15. Day range $1.99–$2.17, opened at $2.13.
- Volume was 1.19M shares, 2.1x its 50-day average of 559.73K — unusually heavy trading.
- Price is -33.8% vs its 50-day average ($3.04) and -44.0% vs its 200-day average ($3.59).
- 52-week range $1.99–$5.55; today's close sits at 1% of that range, 63.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — VYGR slides 5.3% to $2.15, a 52-week low on 1.9x normal volume
- Closed at $2.15, -5.29% vs the prior close of $2.27. Day range $2.14–$2.26, opened at $2.24.
- Volume was 1.06M shares, 1.9x its 50-day average of 550.72K — unusually heavy trading.
- Price is -29.7% vs its 50-day average ($3.06) and -40.2% vs its 200-day average ($3.60).
- 52-week range $2.14–$5.55; today's close sits at 0% of that range, 61.3% below the 52-week high.
Oct 12, 2026 — VYGR slides 7.3% to $2.27, a 52-week low
- Closed at $2.27, -7.35% vs the prior close of $2.45. Day range $2.25–$2.47, opened at $2.46.
- Volume was 967.00K shares, 1.8x its 50-day average of 539.76K.
- Price is -26.2% vs its 50-day average ($3.07) and -37.1% vs its 200-day average ($3.61).
- 52-week range $2.25–$5.55; today's close sits at 1% of that range, 59.1% below the 52-week high.
Oct 9, 2026 — VYGR jumps 3.4% to $2.45
- Closed at $2.45, +3.38% vs the prior close of $2.37. Day range $2.35–$2.52, opened at $2.36.
- Volume was 694.40K shares, 1.3x its 50-day average of 532.76K.
- Price is -20.7% vs its 50-day average ($3.09) and -32.2% vs its 200-day average ($3.61).
- 52-week range $2.33–$5.55; today's close sits at 4% of that range, 55.9% below the 52-week high.
Oct 8, 2026 — VYGR slides 4.0% to $2.37, a 52-week low
- Closed at $2.37, -4.05% vs the prior close of $2.47. Day range $2.33–$2.46, opened at $2.44.
- Volume was 932.20K shares, 1.8x its 50-day average of 525.93K.
- Price is -23.6% vs its 50-day average ($3.10) and -34.6% vs its 200-day average ($3.62).
- 52-week range $2.33–$5.55; today's close sits at 1% of that range, 57.3% below the 52-week high.
Oct 7, 2026 — VYGR rises 0.4% to $2.47
- Closed at $2.47, +0.41% vs the prior close of $2.46. Day range $2.41–$2.50, opened at $2.44.
- Volume was 763.20K shares, 1.5x its 50-day average of 520.46K.
- Price is -20.7% vs its 50-day average ($3.12) and -32.0% vs its 200-day average ($3.63).
- 52-week range $2.39–$5.55; today's close sits at 3% of that range, 55.5% below the 52-week high.
Oct 6, 2026 — VYGR ends flat (+0.0%) to $2.46
- Closed at $2.46, +0.00% vs the prior close of $2.46. Day range $2.41–$2.50, opened at $2.46.
- Volume was 617.70K shares, 1.2x its 50-day average of 522.38K.
- Price is -21.3% vs its 50-day average ($3.13) and -32.4% vs its 200-day average ($3.64).
- 52-week range $2.39–$5.55; today's close sits at 2% of that range, 55.7% below the 52-week high.
Oct 5, 2026 — VYGR rises 0.4% to $2.46 on 2.8x normal volume
- Closed at $2.46, +0.41% vs the prior close of $2.45. Day range $2.39–$2.55, opened at $2.43.
- Volume was 1.39M shares, 2.8x its 50-day average of 504.23K — unusually heavy trading.
- Price is -21.7% vs its 50-day average ($3.14) and -32.6% vs its 200-day average ($3.65).
- 52-week range $2.39–$5.55; today's close sits at 2% of that range, 55.7% below the 52-week high.
Oct 2, 2026 — VYGR slides 8.6% to $2.45, a 52-week low on 2.3x normal volume
- Closed at $2.45, -8.58% vs the prior close of $2.68. Day range $2.42–$2.73, opened at $2.72.
- Volume was 1.17M shares, 2.3x its 50-day average of 505.51K — unusually heavy trading.
- Price is -22.3% vs its 50-day average ($3.15) and -33.0% vs its 200-day average ($3.66).
- 52-week range $2.42–$5.55; today's close sits at 1% of that range, 55.9% below the 52-week high.
VYGR latest news & SEC filings
Every SEC filing by or about VYGR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $3.17M (prior year $5.20M) (-39.1% vs Jun 30, 2025)
- Net income: -$24.47M (prior year -$33.38M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.40 (prior year -$0.57) (loss narrowed vs Jun 30, 2025)
Jul 31, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade VYGR
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 9, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.41% (largest 8.6%). That is a volatile stock.
- Liquidity: about 784.39K shares (≈$1.49M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.90 vs a range of $1.89–$5.55 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Alfred Sandrock sold 11,511 shares on Apr 2, 2026.
- Latest filings: 8-K Aug 6, 2026; 10-Q Aug 6, 2026; 8-K Jul 13, 2026.
- Share count: 61.62M shares outstanding (Jul 30, 2026), +11.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
VYGR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.05 | 2.05 | 1.89 | 1.90 | 573.21K |
| Oct 15, 2026 | 2.00 | 2.10 | 2.00 | 2.06 | 719.30K |
| Oct 14, 2026 | 2.13 | 2.17 | 1.99 | 2.01 | 1.19M |
| Oct 13, 2026 | 2.24 | 2.26 | 2.14 | 2.15 | 1.06M |
| Oct 12, 2026 | 2.46 | 2.47 | 2.25 | 2.27 | 967.00K |
| Oct 9, 2026 | 2.36 | 2.52 | 2.35 | 2.45 | 694.40K |
| Oct 8, 2026 | 2.44 | 2.46 | 2.33 | 2.37 | 932.20K |
| Oct 7, 2026 | 2.44 | 2.50 | 2.41 | 2.47 | 763.20K |
| Oct 6, 2026 | 2.46 | 2.50 | 2.41 | 2.46 | 617.70K |
| Oct 5, 2026 | 2.43 | 2.55 | 2.39 | 2.46 | 1.39M |
| Oct 2, 2026 | 2.72 | 2.73 | 2.42 | 2.45 | 1.17M |
| Oct 1, 2026 | 2.67 | 2.75 | 2.63 | 2.68 | 600.10K |
| Sep 30, 2026 | 2.66 | 2.72 | 2.61 | 2.68 | 598.50K |
| Sep 29, 2026 | 2.70 | 2.70 | 2.58 | 2.64 | 618.60K |
| Sep 28, 2026 | 2.68 | 2.73 | 2.61 | 2.70 | 646.10K |
| Sep 25, 2026 | 2.78 | 2.79 | 2.64 | 2.68 | 719.90K |
| Sep 24, 2026 | 2.87 | 2.88 | 2.71 | 2.80 | 1.09M |
| Sep 23, 2026 | 3.14 | 3.14 | 2.87 | 2.87 | 690.70K |
| Sep 22, 2026 | 3.09 | 3.17 | 3.08 | 3.14 | 341.50K |
| Sep 21, 2026 | 3.13 | 3.16 | 3.05 | 3.08 | 292.70K |
About Voyager Therapeutics
Voyager Therapeutics (VYGR) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in LEXINGTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1640266.
VYGR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Grace Colon | Director | Jun 11, 2026 |
| James A Geraghty | Director | Jun 11, 2026 |
| Michael J Higgins | Director | Jun 11, 2026 |
| Steven Hyman | Director | Jun 11, 2026 |
| Catherine J Mackey | Director | Jun 11, 2026 |
| Jude Onyia | Director | Jun 11, 2026 |
| Glenn Pierce | Director | Jun 11, 2026 |
| George A Scangos | Director | Jun 11, 2026 |
| Alfred Sandrock | President and CEO | Apr 3, 2026 |
| Nancy Vitale | Director | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Todd Alfred Carter | Chief Scientific Officer | Feb 26, 2026 |
| Toby Ferguson | Chief Medical Officer | Feb 10, 2026 |
| Nathan D. Jorgensen | Chief Financial Officer | Feb 26, 2026 |
| Amy Quinlan | Principal Accounting Officer | May 18, 2026 |
| Alfred Sandrock | President and CEO | Apr 3, 2026 |
| Gregory L. Shiferman | SVP and General Counsel | Apr 3, 2026 |
| Robin Swartz | COO & CBO | Feb 26, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 2, 2026 | Alfred Sandrock | Sale | 11,511 | $3.87 |
| Apr 2, 2026 | Alfred Sandrock | Sale | 11,511 | $3.87 |
| Apr 2, 2026 | Alfred Sandrock | Sale | 11,511 | $3.87 |
| Apr 2, 2026 | Alfred Sandrock | Sale | 11,511 | $3.87 |
| Feb 24, 2026 | Alfred Sandrock | Sale | 14,197 | $3.79 |
| Feb 24, 2026 | Alfred Sandrock | Sale | 14,197 | $3.79 |
| Feb 24, 2026 | Alfred Sandrock | Sale | 14,197 | $3.79 |
| Feb 24, 2026 | Alfred Sandrock | Sale | 14,197 | $3.79 |
| Feb 24, 2026 | Todd Alfred Carter | Sale | 4,174 | $3.76 |
| Feb 24, 2026 | Todd Alfred Carter | Sale | 4,174 | $3.76 |
| Feb 24, 2026 | Todd Alfred Carter | Sale | 4,174 | $3.76 |
| Feb 24, 2026 | Todd Alfred Carter | Sale | 4,174 | $3.76 |
| Feb 24, 2026 | Robin Swartz | Sale | 6,458 | $3.77 |
| Feb 24, 2026 | Robin Swartz | Sale | 6,458 | $3.77 |
| Feb 24, 2026 | Robin Swartz | Sale | 6,458 | $3.77 |
VYGR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $40.37M | $-119.72M | -2.04 | $-132.47M |
| Dec 31, 2024 | $80.00M | $-65.00M | -1.13 | $-15.31M |
| Dec 31, 2023 | $250.01M | $132.33M | 2.97 | $77.92M |
| Dec 31, 2022 | $40.91M | $-46.41M | -1.21 | $-12.51M |
| Dec 31, 2021 | $37.41M | $-71.20M | -1.89 | $-53.52M |
Latest balance sheet: total assets $197.75M, total liabilities $43.38M, cash $35.77M (as of Jun 30, 2026).
VYGR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $3.13 |
| May 7, 2026 | 8-K Item 2.02 (results) | $3.96 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $4.11 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $4.26 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $3.40 |
| May 6, 2025 | 8-K Item 2.02 (results) | $3.25 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $3.97 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $6.83 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
| Jan 2, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on VYGR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.